Примери за използване на Melphalan and prednisone на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
No dose adjustment is proposed for patients older than 75 years who are treated with lenalidomide in combination with melphalan and prednisone.
Recommended posology for VELCADE in combination with melphalan and prednisone for patients with previously untreated multiple myeloma Twice weekly VELCADE(cycles 1-4).
re-initiation of treatment for combination therapy with melphalan and prednisone Prior to initiating a new cycle of therapy.
ADRs reported in clinical studies in patients with multiple myeloma treated with lenalidomide in combination with dexamethasone, or with melphalan and prednisone System Organ.
you will receive VELCADE together with two other medicines containing melphalan and prednisone.
When used in combination with melphalan and prednisone, Velcade is given twice a week on weeks 1,
Overall, the safety profile of patients treated with VELCADE in monotherapy was similar to that observed in patients treated with VELCADE in combination with melphalan and prednisone.
Melphalan and prednisone were dosed at 0.25 mg/kg/day
was administered concomitantly with high dose dexamethasone, and bortezomib, melphalan and prednisone in multiple myeloma patients.
Patients receiving melphalan and prednisone survived for an average of 33.2 months from the start of the study,
In combination with the medicines melphalan and prednisone, for patients whose disease has not been previously treated
Patients receiving melphalan and prednisone lived for an average of 33.2 months from the start of the study,
Bortezomib therapy should be withheld when the platelet count is< 25,000/μl or in combination with melphalan and prednisone when the platelet count is≤ 30,000/μl(see section 4.2).
Thalidomide Celgene in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma,
Frequencies given are based on the observations during a pivotal comparative clinical study investigating the effect of thalidomide in combination with melphalan and prednisone in previously untreated multiple myeloma patients.
VELCADE in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with bone marrow transplant.
dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
This increase was not observed in clinical trials of newly diagnosed multiple myeloma in patients taking lenalidomide in combination with low dose dexamethasone compared to thalidomide in combination with melphalan and prednisone.
VELCADE in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
you are not suitable for blood stem cell transplantation you will receive VELCADE together with two other medicines; melphalan and prednisone.